Locations:
Search
Should institutions adopt “time to treatment” as a new quality metric?
A multidisciplinary team of Cleveland Clinic scientists looks to evolution for answers
Drug beats standard care for the treatment of relapsed or refractory ALL
APE2 may hold the key to reducing cisplatin toxicity
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Endoluminal surgery provides new treatment options
Pairing low-frequency ultrasound with microbubble resonators to penetrate the blood-brain barrier
Slight deviation from treatment paradigm salvages significant anatomy
Large validation study corroborates previous findings, sets the stage for clinical use
Truly personalized radiotherapy may be within reach
Molecular targeted therapies and other treatments offer new options
Advertisement
Advertisement